Background Emerging data suggest that statins, aspirin and metformin may protect against
hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited …

Summary Background Chemoprevention with NSAIDs, including aspirin, and anti‐platelet
therapy (APT), has been suggested to reduce the incidence and recurrence of …

Background Emerging laboratory and animal studies suggest that aspirin may prevent non-
alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma (HCC), however …

A total of twenty-five novel carboxylic acid, methylester, methylamide or cyano nonsteroidal
anti-inflammatory drug (NSAID) derivatives incorporating Se in the chemical form of …

Hepatocellular carcinoma (HCC) is the third‐leading cause of cancer‐related death
worldwide, with a growing incidence and poor prognosis. While some recent studies …

Preclinical and clinical studies provide evidence for aspirin as a preventative agent for
cancer. Compelling direct evidence supports a chemopreventive effect of aspirin in …

The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication
of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological …

Abstract Background & Aims Aspirin and statins have been suggested to prevent
hepatocellular carcinoma (HCC). However, the combined effects of aspirin and statins on …

Simple Summary Platelets are blood cells, the main function of which is to form clots and
prevent/stop bleeding. However, it has been shown that platelets may be involved in …

Preclinical studies highlighted potential therapeutic applications of aspirin and statins as
anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the …